Alpha 2.0
Login Register
» Authors » Hideki Yasui

Hideki Yasui

Explore the profile of Hideki Yasui including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 122
Citations 854
Followers 0
Related Specialties
Pulmonary Medicine
Oncology
Allergy & Immunology
Top 10 Co-Authors
Takafumi Suda
Naoki Inui
Tomoyuki Fujisawa
Noriyuki Enomoto
Masato Karayama
Hironao Hozumi
Yuzo Suzuki
Kazuki Furuhashi
Yutaro Nakamura
Yusuke Inoue
Published In
Respir Med
Sci Rep
Respir Res
Respir Investig
Nihon Kokyuki Gakkai Zasshi
Affiliations
Soon will be listed here.
Recent Articles
1.
Lethal co-expression intolerance underlies the mutually exclusive expression of ASCL1 and NEUROD1 in SCLC cells
Watanabe H, Inoue Y, Tsuchiya K, Asada K, Suzuki M, Ogawa H, et al.
NPJ Precis Oncol . 2025 Mar; 9(1):74. PMID: 40082639
Small cell lung cancer (SCLC) subtypes, defined by the expression of lineage-specific transcription factors (TFs), are thought to be mutually exclusive, with intra-tumoral heterogeneities. This study investigated the mechanism underlying...
2.
Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis
Nakai S, Karayama M, Inoue Y, Yasui H, Hozumi H, Suzuki Y, et al.
Respir Investig . 2025 Feb; 63(3):259-264. PMID: 39970788
Background: Immune-related pneumonitis (irP) is a severe immune-related adverse event that can occur after treatment with immune checkpoint inhibitors (ICIs); accurate monitoring and early diagnosis are crucial. Serum Krebs von...
3.
Outcomes of COVID-19 in the Omicron-predominant wave: large-scale real-world data analysis with a comparison to influenza
Miyashita K, Hozumi H, Furuhashi K, Nakatani E, Inoue Y, Yasui H, et al.
Pneumonia (Nathan) . 2025 Feb; 17(1):3. PMID: 39905566
Purpose: Studies on COVID-19 mortality during the Omicron-predominant wave have focused primarily on the inpatient/emergency room setting, and real-world data including both inpatients and outpatients are lacking. Methods: Patients diagnosed...
4.
Prevalence and clinical features of progressive pulmonary fibrosis in patients with unclassifiable idiopathic interstitial pneumonia: A post hoc analysis of prospective multicenter registry
Kono M, Enomoto N, Inoue Y, Yasui H, Karayama M, Suzuki Y, et al.
Respir Investig . 2025 Feb; 63(2):216-223. PMID: 39892159
Background: Idiopathic interstitial pneumonias (IIPs) may remain unclassifiable owing to inadequate, nonspecific, or conflicting clinical, radiological, or histopathological findings despite multidisciplinary discussion (MDD). Unclassifiable IIP (UCIIP) is a heterogeneous disease...
5.
Association of interstitial lung abnormalities with cytotoxic agent-induced pneumonitis in patients with malignancy
Oishi K, Hozumi H, Yoshizawa N, Ichikawa S, Inoue Y, Yasui H, et al.
Respir Med . 2024 Dec; 237:107924. PMID: 39733813
Background And Objective: The association between interstitial lung abnormalities (ILA) and various conditions and diseases, including drug-related pneumonitis (DRP), has been reported. However, the association of the presence of ILA...
6.
Association between the HAL score and the development of progressive pulmonary fibrosis in idiopathic interstitial pneumonia: A prospective observational study
Nakayasu H, Karayama M, Enomoto N, Inoue Y, Yasui H, Suzuki Y, et al.
Respir Investig . 2024 Dec; 63(1):138-145. PMID: 39693847
Background: Progressive pulmonary fibrosis (PPF) is a critical concern in interstitial lung disease (ILD) management. The HAL score, which incorporates honeycombing (H), age >75 years (A), and serum lactate dehydrogenase...
7.
Factors associated with uncontrolled severe asthma in the biologic era
Yasui H, Oishi K, Nihashi F, Furuhashi K, Fujisawa T, Inoue Y, et al.
Respir Med . 2024 Nov; 236():107881. PMID: 39580034
Background: Despite the development of biologics for severe asthma, individuals with uncontrolled status persist, posing a significant social problem. This multicenter prospective study aimed to identify factors associated with the...
8.
Prognostic Awareness and Knowledge of Acute Exacerbation in Patients Dying with Interstitial Lung Disease: A Nationwide Survey
Koyauchi T, Fujisawa T, Miyashita M, Mori M, Morita T, Yazawa S, et al.
Ann Am Thorac Soc . 2024 Nov; 22(3):395-402. PMID: 39513985
Accurate prognostic awareness (PA) and knowledge of the disease are critical for decision-making regarding treatment options, advance care planning, and end-of-life care. However, they have not been investigated in patients...
9.
Hypnotics and Mortality in Idiopathic Pulmonary Fibrosis: Hospital and National Data-Based Analysis
Hozumi H, Endo Y, Kono M, Hasegawa H, Miyashita K, Naoi H, et al.
Chest . 2024 Nov; PMID: 39510406
Background: Patients with idiopathic pulmonary fibrosis (IPF) may experience insomnia and use hypnotics. However, the effect of the use of hypnotics on their clinical course remains unclear. Research Question: Is...
10.
Association of constipation with the survival of patients with idiopathic interstitial pneumonias
Takuma S, Mori K, Karayama M, Inoue Y, Yasui H, Hozumi H, et al.
Respir Investig . 2024 Oct; 62(6):1204-1208. PMID: 39476439
Background: Constipation is associated with the prognosis of several chronic diseases. However, the effect of constipation on the prognosis of idiopathic interstitial pneumonias (IIPs) remains unclear. This study aimed to...